Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential.

Détails

Ressource 1Télécharger: 36975001_BIB_CF6CBA8233D2.pdf (2153.46 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_CF6CBA8233D2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Redox and Immune Signaling in Schizophrenia: New Therapeutic Potential.
Périodique
The international journal of neuropsychopharmacology
Auteur⸱e⸱s
Dwir D., Khadimallah I., Xin L., Rahman M., Du F., Öngür D., Do K.Q.
ISSN
1469-5111 (Electronic)
ISSN-L
1461-1457
Statut éditorial
Publié
Date de publication
31/05/2023
Peer-reviewed
Oui
Volume
26
Numéro
5
Pages
309-321
Langue
anglais
Notes
Publication types: Review ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Résumé
Redox biology and immune signaling play major roles in the body, including in brain function. A rapidly growing literature also suggests that redox and immune abnormalities are implicated in neuropsychiatric conditions such as schizophrenia (SZ), bipolar disorder, autism, and epilepsy. In this article we review this literature, its implications for the pathophysiology of SZ, and the potential for development of novel treatment interventions targeting redox and immune signaling. Redox biology and immune signaling in the brain are complex and not fully understood; in addition, there are discrepancies in the literature, especially in patient-oriented studies. Nevertheless, it is clear that abnormalities arise in SZ from an interaction between genetic and environmental factors during sensitive periods of brain development, and these abnormalities disrupt local circuits and long-range connectivity. Interventions that correct these abnormalities may be effective in normalizing brain function in psychotic disorders, especially in early phases of illness.
Mots-clé
Humans, Schizophrenia/drug therapy, Schizophrenia/genetics, Oxidative Stress/physiology, Psychotic Disorders, Oxidation-Reduction, Bipolar Disorder, NAD/NADH, Oxidative stress, glutathione, neuro-inflammation, parvalbumin neurons, schizophrenia
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/04/2023 10:50
Dernière modification de la notice
09/08/2024 15:06
Données d'usage